FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810593821> ?p ?o ?g. }

• W2810593821 abstract "Melanoma is a molecularly heterogeneous disease with many genetic mutations and altered signaling pathways. Activating mutations in the BRAF oncogene are observed in approximately 50% of cutaneous melanomas and the use of BRAF inhibitor (BRAFi) compounds has been reported to improve the outcome of patients with BRAF-mutated metastatic melanoma. However, the majority of these patients develop resistance within 6-8 months following the initiation of BRAFi treatment. In this study, we examined the possible use of the poly(ADP-ribose) polymerase 1 (PARP1) inhibitor, ABT-888 (veliparib), as a novel molecule that may be successfully employed in the treatment of BRAFi-resistant melanoma cells. Sensitive and resistant to BRAFi dabrafenib A375 cells were exposed to increasing concentrations of ABT-888. Cell viability and apoptosis were assessed by MTT assay and Annexin V-FITC analysis, respectively. The cell migratory and invasive ability was investigated using the xCELLigence technology and Boyden chamber assays, respectively. ABT-888 was found to reduce cell viability and exhibited pro-apoptotic activity in melanoma cell lines, independently from the BRAF/NRAS mutation status, in a dose-dependent manner, with the maximal effect being reached in the 25-50 µM concentration range. Moreover, ABT-888 promoted apoptosis in both the sensitive and resistant A375 cells, suggesting that ABT-888 may be useful in the treatment of BRAFi-resistant subsets of melanoma cells. Finally, in accordance with the involvement of PARP1 in actin cytoskeletal machinery, we found that the cytoskeletal organization, motility and invasive capability of both the A375 and A375R cells decreased upon exposure to 5 µM ABT-888 for 24 h. On the whole, the findings of this study highlight the pivotal role of PARP1 in the migration and invasion of melanoma cells, suggesting that ABT-888 may indeed be effective, not only as a pro-apoptotic drug for use in the treatment of BRAFi-resistant melanoma cells, but also in suppressing their migratory and invasive activities." @default.
• W2810593821 created "2018-07-10" @default.
• W2810593821 creator A5006977348 @default.
• W2810593821 creator A5008816822 @default.
• W2810593821 creator A5015675599 @default.
• W2810593821 creator A5029398339 @default.
• W2810593821 creator A5042407442 @default.
• W2810593821 creator A5044436120 @default.
• W2810593821 creator A5048796106 @default.
• W2810593821 creator A5066163177 @default.
• W2810593821 creator A5077141337 @default.
• W2810593821 creator A5083575894 @default.
• W2810593821 date "2018-06-27" @default.
• W2810593821 modified "2023-10-01" @default.
• W2810593821 title "Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells" @default.
• W2810593821 cites W1511924115 @default.
• W2810593821 cites W1825629489 @default.
• W2810593821 cites W1861714325 @default.
• W2810593821 cites W1882891727 @default.
• W2810593821 cites W1982443780 @default.
• W2810593821 cites W1987206970 @default.
• W2810593821 cites W2004422079 @default.
• W2810593821 cites W2006850592 @default.
• W2810593821 cites W2011071742 @default.
• W2810593821 cites W2018155127 @default.
• W2810593821 cites W2025063281 @default.
• W2810593821 cites W2032211985 @default.
• W2810593821 cites W2043058822 @default.
• W2810593821 cites W2044029217 @default.
• W2810593821 cites W2049171090 @default.
• W2810593821 cites W2085971843 @default.
• W2810593821 cites W2086038769 @default.
• W2810593821 cites W2096575630 @default.
• W2810593821 cites W2103557568 @default.
• W2810593821 cites W2104148147 @default.
• W2810593821 cites W2105660237 @default.
• W2810593821 cites W2106390123 @default.
• W2810593821 cites W2106543129 @default.
• W2810593821 cites W2110487265 @default.
• W2810593821 cites W2111365327 @default.
• W2810593821 cites W2128542677 @default.
• W2810593821 cites W2131040858 @default.
• W2810593821 cites W2131670056 @default.
• W2810593821 cites W2132867241 @default.
• W2810593821 cites W2133411473 @default.
• W2810593821 cites W2137903987 @default.
• W2810593821 cites W2141674733 @default.
• W2810593821 cites W2150089707 @default.
• W2810593821 cites W2154841567 @default.
• W2810593821 cites W2155851270 @default.
• W2810593821 cites W2163188200 @default.
• W2810593821 cites W2163294504 @default.
• W2810593821 cites W2168420784 @default.
• W2810593821 cites W2168711434 @default.
• W2810593821 cites W2245150875 @default.
• W2810593821 cites W2254594392 @default.
• W2810593821 cites W2401574182 @default.
• W2810593821 cites W2491982852 @default.
• W2810593821 cites W2500891884 @default.
• W2810593821 cites W2527281379 @default.
• W2810593821 cites W2590276694 @default.
• W2810593821 cites W2607866982 @default.
• W2810593821 cites W2731189994 @default.
• W2810593821 cites W2766552679 @default.
• W2810593821 cites W2775284833 @default.
• W2810593821 cites W2791962996 @default.
• W2810593821 cites W4211123988 @default.
• W2810593821 doi "https://doi.org/10.3892/ijo.2018.4457" @default.
• W2810593821 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6065454" @default.
• W2810593821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29956724" @default.
• W2810593821 hasPublicationYear "2018" @default.
• W2810593821 type Work @default.
• W2810593821 sameAs 2810593821 @default.
• W2810593821 citedByCount "10" @default.
• W2810593821 countsByYear W28105938212019 @default.
• W2810593821 countsByYear W28105938212020 @default.
• W2810593821 countsByYear W28105938212021 @default.
• W2810593821 countsByYear W28105938212022 @default.
• W2810593821 countsByYear W28105938212023 @default.
• W2810593821 crossrefType "journal-article" @default.
• W2810593821 hasAuthorship W2810593821A5006977348 @default.
• W2810593821 hasAuthorship W2810593821A5008816822 @default.
• W2810593821 hasAuthorship W2810593821A5015675599 @default.
• W2810593821 hasAuthorship W2810593821A5029398339 @default.
• W2810593821 hasAuthorship W2810593821A5042407442 @default.
• W2810593821 hasAuthorship W2810593821A5044436120 @default.
• W2810593821 hasAuthorship W2810593821A5048796106 @default.
• W2810593821 hasAuthorship W2810593821A5066163177 @default.
• W2810593821 hasAuthorship W2810593821A5077141337 @default.
• W2810593821 hasAuthorship W2810593821A5083575894 @default.
• W2810593821 hasBestOaLocation W28105938211 @default.
• W2810593821 hasConcept C121608353 @default.
• W2810593821 hasConcept C1491633281 @default.
• W2810593821 hasConcept C190283241 @default.
• W2810593821 hasConcept C21790070 @default.
• W2810593821 hasConcept C2777658100 @default.
• W2810593821 hasConcept C2781018059 @default.
• W2810593821 hasConcept C2781187634 @default.
• W2810593821 hasConcept C29537977 @default.
• W2810593821 hasConcept C502942594 @default.

• next